Cargando…
The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non‐small cell lung cancer
BACKGROUND: The recurrence rate of non‐small cell lung cancer (NSCLC) is as high as 30%, even in the cancer with pathological stage I disease. Therefore, identifying factors predictive of high‐risk pathological recurrence is important. However, few studies have examined the genetic status of these t...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587933/ https://www.ncbi.nlm.nih.gov/pubmed/37712717 http://dx.doi.org/10.1002/cam4.6535 |
_version_ | 1785123469031112704 |
---|---|
author | Honda, Takayuki Seto, Katsutoshi Endo, Satoshi Takemoto, Akira Tanimoto, Kousuke Kobayashi, Masashi Kitano, Masatake Sakakibara, Rie Mitsumura, Takahiro Ishibashi, Hironori Inazawa, Johji Tanaka, Toshihiro Miyazaki, Yasunari Okubo, Kenichi |
author_facet | Honda, Takayuki Seto, Katsutoshi Endo, Satoshi Takemoto, Akira Tanimoto, Kousuke Kobayashi, Masashi Kitano, Masatake Sakakibara, Rie Mitsumura, Takahiro Ishibashi, Hironori Inazawa, Johji Tanaka, Toshihiro Miyazaki, Yasunari Okubo, Kenichi |
author_sort | Honda, Takayuki |
collection | PubMed |
description | BACKGROUND: The recurrence rate of non‐small cell lung cancer (NSCLC) is as high as 30%, even in the cancer with pathological stage I disease. Therefore, identifying factors predictive of high‐risk pathological recurrence is important. However, few studies have examined the genetic status of these tumors and its relationship to prognosis. MATERIALS AND METHODS: A cohort of 328 cases of primary lung cancer that underwent complete resection at Tokyo Medical and Dental University (TMDU) was screened for 440 cancer‐associated genes using panel testing. Further analyses included 92 cases of pathological stage I NSCLC who did not receive adjuvant chemotherapy. Ridge regression was performed to identify association studies mutational status and postoperative recurrence. These data were then validated using clinical and genetic data from 56 patients in The Cancer Genome Atlas (TCGA). RESULTS: Mutations in TP53, RAS signaling genes KRAS and HRAS, and EGFR were recurrently detected. Ridge regression analysis relevant to recurrence, as well as survival analysis, performed using data from the TMDU cohort revealed significantly shorter relapse‐free survival (RFS) for patients with RAS signaling or TP53 gene mutations than for those without (log‐rank test, p = 0.00090). This statistical trend was also suggested in the TCGA cohort (log‐rank test, p = 0.10). CONCLUSION: Mutations in RAS signaling genes and/or TP53 could be useful for the prediction of shorter RFS of patients with stage I NSCLC. |
format | Online Article Text |
id | pubmed-10587933 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-105879332023-10-21 The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non‐small cell lung cancer Honda, Takayuki Seto, Katsutoshi Endo, Satoshi Takemoto, Akira Tanimoto, Kousuke Kobayashi, Masashi Kitano, Masatake Sakakibara, Rie Mitsumura, Takahiro Ishibashi, Hironori Inazawa, Johji Tanaka, Toshihiro Miyazaki, Yasunari Okubo, Kenichi Cancer Med RESEARCH ARTICLES BACKGROUND: The recurrence rate of non‐small cell lung cancer (NSCLC) is as high as 30%, even in the cancer with pathological stage I disease. Therefore, identifying factors predictive of high‐risk pathological recurrence is important. However, few studies have examined the genetic status of these tumors and its relationship to prognosis. MATERIALS AND METHODS: A cohort of 328 cases of primary lung cancer that underwent complete resection at Tokyo Medical and Dental University (TMDU) was screened for 440 cancer‐associated genes using panel testing. Further analyses included 92 cases of pathological stage I NSCLC who did not receive adjuvant chemotherapy. Ridge regression was performed to identify association studies mutational status and postoperative recurrence. These data were then validated using clinical and genetic data from 56 patients in The Cancer Genome Atlas (TCGA). RESULTS: Mutations in TP53, RAS signaling genes KRAS and HRAS, and EGFR were recurrently detected. Ridge regression analysis relevant to recurrence, as well as survival analysis, performed using data from the TMDU cohort revealed significantly shorter relapse‐free survival (RFS) for patients with RAS signaling or TP53 gene mutations than for those without (log‐rank test, p = 0.00090). This statistical trend was also suggested in the TCGA cohort (log‐rank test, p = 0.10). CONCLUSION: Mutations in RAS signaling genes and/or TP53 could be useful for the prediction of shorter RFS of patients with stage I NSCLC. John Wiley and Sons Inc. 2023-09-15 /pmc/articles/PMC10587933/ /pubmed/37712717 http://dx.doi.org/10.1002/cam4.6535 Text en © 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | RESEARCH ARTICLES Honda, Takayuki Seto, Katsutoshi Endo, Satoshi Takemoto, Akira Tanimoto, Kousuke Kobayashi, Masashi Kitano, Masatake Sakakibara, Rie Mitsumura, Takahiro Ishibashi, Hironori Inazawa, Johji Tanaka, Toshihiro Miyazaki, Yasunari Okubo, Kenichi The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non‐small cell lung cancer |
title | The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non‐small cell lung cancer |
title_full | The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non‐small cell lung cancer |
title_fullStr | The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non‐small cell lung cancer |
title_full_unstemmed | The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non‐small cell lung cancer |
title_short | The possibility of mutations of RAS signaling genes and/or TP53 in combination as a negative prognostic impact on pathological stage I non‐small cell lung cancer |
title_sort | possibility of mutations of ras signaling genes and/or tp53 in combination as a negative prognostic impact on pathological stage i non‐small cell lung cancer |
topic | RESEARCH ARTICLES |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10587933/ https://www.ncbi.nlm.nih.gov/pubmed/37712717 http://dx.doi.org/10.1002/cam4.6535 |
work_keys_str_mv | AT hondatakayuki thepossibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT setokatsutoshi thepossibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT endosatoshi thepossibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT takemotoakira thepossibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT tanimotokousuke thepossibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT kobayashimasashi thepossibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT kitanomasatake thepossibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT sakakibararie thepossibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT mitsumuratakahiro thepossibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT ishibashihironori thepossibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT inazawajohji thepossibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT tanakatoshihiro thepossibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT miyazakiyasunari thepossibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT okubokenichi thepossibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT hondatakayuki possibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT setokatsutoshi possibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT endosatoshi possibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT takemotoakira possibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT tanimotokousuke possibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT kobayashimasashi possibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT kitanomasatake possibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT sakakibararie possibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT mitsumuratakahiro possibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT ishibashihironori possibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT inazawajohji possibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT tanakatoshihiro possibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT miyazakiyasunari possibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer AT okubokenichi possibilityofmutationsofrassignalinggenesandortp53incombinationasanegativeprognosticimpactonpathologicalstageinonsmallcelllungcancer |